Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on June 9, 2023. The filing reports on corporate governance changes, specifically the appointment of new executive officers effective September 1, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
The primary material change reported is the restructuring of the finance leadership team effective September 1, 2023:
- Robert E. Funck, Jr. appointed Executive Vice President, Finance.
- Philip P. Boudreau appointed Senior Vice President, Finance and Chief Financial Officer (CFO), reporting to Mr. Funck.
- John A. McCoy, Jr. appointed Vice President, Controller.
Management Commentary and Compensation
Management provided details regarding the compensation for the newly appointed CFO:
- Philip P. Boudreau: Base salary of $600,000 with a target annual bonus opportunity of 90% of base salary. He will also enter into a Change in Control Agreement.
- John A. McCoy, Jr.: Compensation will include a base salary, annual incentive, long-term incentive, and other benefits consistent with similarly situated executive officers.
No guidance, outlook, risks, or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the leadership transition (September 1, 2023).
- Review the Change in Control Agreement referenced for Philip P. Boudreau (Exhibit 10.1 to the November 30, 2012 8-K).
- Confirm the reporting structure where the CFO now reports to the Executive Vice President, Finance.